418 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca http://www.zacks.com/research-daily/362256/top-stock-reports-for-las-vegas-sands-phillips-66-astrazeneca?cid=CS-ZC-FT-362256 Mar 20, 2019 - Top Stock Reports for Las Vegas Sands, Phillips 66 & AstraZeneca
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study http://www.zacks.com/stock/news/361462/phasebio-stock-up-on-positive-data-from-pb2452-phase-i-study?cid=CS-ZC-FT-361462 Mar 19, 2019 - PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/361461/roches-tecentriq-gets-fda-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-361461 Mar 19, 2019 - Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million http://www.zacks.com/stock/news/360866/novartis-nvs-alcon-acquired-powervision-for-%24285-million?cid=CS-ZC-FT-360866 Mar 18, 2019 - Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Top Research Reports for Merck, Adobe & Broadcom http://www.zacks.com/research-daily/360711/top-research-reports-for-merck-adobe-broadcom?cid=CS-ZC-FT-360711 Mar 18, 2019 - Top Research Reports for Merck, Adobe & Broadcom
AstraZeneca Up This Year on New Drugs & Pipeline Progress http://www.zacks.com/stock/news/359997/astrazeneca-up-this-year-on-new-drugs-pipeline-progress?cid=CS-ZC-FT-359997 Mar 18, 2019 - AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
3 Dividend Stocks That Should Pay You the Rest of Your Life https://www.fool.com/investing/2019/03/17/3-dividend-stocks-that-should-pay-you-the-rest-of.aspx?source=iedfolrf0000001 Mar 17, 2019 - These dividend stocks could send you checks for a lifetime.
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag http://www.zacks.com/stock/news/359874/aveo-pharmaceuticals-aveo-q4-earnings-beat-revenues-lag?cid=CS-ZC-FT-359874 Mar 15, 2019 - AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/359869/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-359869 Mar 15, 2019 - Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
Here's Why Momentum Investors Will Love Astrazeneca (AZN) http://www.zacks.com/stock/news/359525/heres-why-momentum-investors-will-love-astrazeneca-azn?cid=CS-ZC-FT-359525 Mar 14, 2019 - Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Pages: 12345678...42

<<<Page 3>